A stronger team
We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.
Jesper has a high level of strategic proficiency and business acumen with a solid background from Lundbeck as a senior project manager. His experience spans 18 years of project management roles in the context of small molecules and biologics, and he has a proven track record in interactions with authorities in the EU, US, Japan, and China.
For 11 years, Jesper served as global project lead for the successful development of Brintellix® from preclinical development through the I, II and III phases, and on to registration and launch. Before that, he managed several other well-known projects through all phases. Jesper is also known for his excellence in stakeholder communications and is a member of consultancy group KLIFO.
With Jesper on board, our team now has all the skills required for the journey ahead. We are convinced that Jesper will make a strong contribution to the success of PN6047
A stronger team
We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.
Jesper has a high level of strategic proficiency and business acumen with a solid background from Lundbeck as a senior project manager. His experience spans 18 years of project management roles in the context of small molecules and biologics, and he has a proven track record in interactions with authorities in the EU, US, Japan, and China.
For 11 years, Jesper served as global project lead for the successful development of Brintellix® from preclinical development through the I, II and III phases, and on to registration and launch. Before that, he managed several other well-known projects through all phases. Jesper is also known for his excellence in stakeholder communications and is a member of consultancy group KLIFO.
With Jesper on board, our team now has all the skills required for the journey ahead. We are convinced that Jesper will make a strong contribution to the success of PN6047
Latest news
View all
Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read more
Meet Bengt von Mentzer, founder and Chief scientific advisor
Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more
NIDA funds studies
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read more
Meet Olof Breuer, MD, Clinical pharmacology lead
Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.
Read more